Background Evidence supports magnesium sulphate (MgSO4) for women at risk of imminent
birth at< 32–34 weeks to reduce the likelihood of cerebral palsy in the child. MAGnesium …

Background Administration of magnesium sulphate (MgSO 4) to women with imminent
preterm birth at< 34 weeks is an evidence-based antenatal neuroprotective strategy to …

Background Ordinary meta‐analyses indicate that magnesium sulphate (MgSO4) treatment
in women at imminent risk for preterm delivery decreases the offspring's risk of cerebral …

Background Magnesium sulphate is a common therapy in perinatal care. Its benefits when
given to women at risk of preterm birth for fetal neuroprotection (prevention of cerebral palsy …

Objective The objective is to provide guidelines for the use of antenatal magnesium sulphate
for fetal neuroprotection of the preterm infant. Options Antenatal magnesium sulphate …

Background Babies born preterm are at an increased risk of dying in the first weeks of life,
and those who survive have a higher rate of cerebral palsy (CP) compared with babies born …

Background Magnesium sulphate was introduced for fetal neuroprotection in Australia in
2010. The aim of this study was to determine how often antenatal magnesium sulphate is …

Antenatal magnesium sulphate reduces the risk of cerebral palsy in babies born< 30 weeks'
gestation. A guideline for its use in women at imminent risk of preterm birth was …

Background It is important to establish whether research recommendations regarding
magnesium sulphate for neuroprotection can be readily translated into clinical practice and …

Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …